Bangalore February 15, 2014:- Hyderabad-based biopharmaceutical company Suven Life Sciences Ltd (Suven) secured two product patents from New Zealand corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2029 and 2030 respectively. The granted patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents.
They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia.
With the new patents, Suven has a total of 19 patents from New Zealand. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.- Business Standard
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…